ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 185 filers reported holding ASCENDIS PHARMA A/S in Q3 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $561,410,005 | +1.1% | 5,995,408 | -3.6% | 0.95% | +6.7% |
| Q2 2023 | $555,353,752 | -24.3% | 6,222,451 | -9.1% | 0.89% | -26.0% |
| Q1 2023 | $733,893,130 | -13.2% | 6,844,741 | -1.1% | 1.21% | -19.2% |
| Q4 2022 | $845,183,078 | +14.5% | 6,920,356 | -3.2% | 1.49% | +15.1% |
| Q3 2022 | $738,257,000 | +6.3% | 7,149,493 | -4.3% | 1.30% | +10.6% |
| Q2 2022 | $694,698,000 | -27.9% | 7,473,086 | -9.0% | 1.17% | -7.8% |
| Q1 2022 | $963,870,000 | -9.8% | 8,212,938 | +3.4% | 1.27% | +0.6% |
| Q4 2021 | $1,068,227,000 | -13.9% | 7,940,434 | +2.0% | 1.26% | -16.5% |
| Q3 2021 | $1,240,829,000 | +46.7% | 7,784,860 | +21.1% | 1.52% | +50.1% |
| Q2 2021 | $845,789,000 | +8.5% | 6,429,407 | +6.3% | 1.01% | +2.4% |
| Q1 2021 | $779,323,000 | -19.0% | 6,046,890 | +4.8% | 0.98% | -16.0% |
| Q4 2020 | $961,908,000 | +11.0% | 5,767,527 | +2.7% | 1.17% | -4.2% |
| Q3 2020 | $866,540,000 | +45.3% | 5,615,217 | +39.3% | 1.22% | +28.2% |
| Q2 2020 | $596,259,000 | +106.9% | 4,031,504 | +57.5% | 0.96% | +54.8% |
| Q1 2020 | $288,209,000 | -3.9% | 2,559,356 | +18.7% | 0.62% | +17.5% |
| Q4 2019 | $299,998,000 | +45.6% | 2,156,396 | +0.8% | 0.52% | +34.6% |
| Q3 2019 | $206,093,000 | +12.3% | 2,139,665 | +34.3% | 0.39% | +15.4% |
| Q2 2019 | $183,465,000 | +37.8% | 1,593,267 | +40.9% | 0.34% | +28.5% |
| Q1 2019 | $133,131,000 | +479.1% | 1,131,107 | +208.2% | 0.26% | +405.8% |
| Q4 2018 | $22,989,000 | +40.0% | 366,947 | +58.4% | 0.05% | +67.7% |
| Q3 2018 | $16,416,000 | +183.3% | 231,672 | +166.0% | 0.03% | +158.3% |
| Q2 2018 | $5,795,000 | – | 87,111 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |